Why Is Aardvark Therapeutics Stock Sinking Monday?
Aardvark Therapeutics Inc. (NASDAQ:AARD) shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.
The decision comes as the company is conducting a comprehensive review of safety data.
Observed Side Effects
The company on Friday revealed that it will not announce topline data from the HERO trial as previously anticipated in the third quarter of 2026. This pause was prompted by reversible cardiac observations at higher than target therapeutic doses found during routine safety monitoring in a healthy volunteer study.
Aardvark’s CEO, Tien Lee, emphasized the commitment to patient safety and the importance of evaluating the signals seen at elevated doses of ARD-101. The company plans to continue collaborating closely with the FDA and the Prader-Willi Syndrome community while determining the next steps for its clinical program.
Analyst View
“At this point, it is admittedly difficult to properly assess prospects of ARD-101 in Prader-Willi syndrome given the limited available information,” William Blair wrote in an investor note on Monday.
Analyst Andy T. Hsieh added that due to the severe disruption of the study pause, the ongoing Phase 3 HERO trial may not be fully completed. However, this outcome opens the possibility of the company electing to unblind the study early.
He highlighted that the management announced that greater than half of the target (90 patients) had been completed around mid-January, suggesting that unblinding the HERO study results could yield a sufficient sample size for investors to fully assess the risk/benefit profile of ARD-101.
“Assuming resolution of the cardiac safety event, Aardvark may be able to accelerate and streamline the second pivotal study with increased confidence in its statistical and powering assumptions,” analyst Hsieh commented on Monday.
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $29.78. Recent analyst moves include:
- RBC Capital: Downgraded to Sector Perform (Lowers Target to $6.00) (Mar. 2)
- Stifel: Downgraded to Hold (Lowers Target to $6.00) (Mar. 2)
- Morgan Stanley: Downgraded to Equal-Weight (Lowers Target to $7) (Mar. 2).
- HC Wainwright: Downgrades to Neutral (Mar. 2).
AARD Price Action: Aardvark Therapeutics shares were down 55.88% at $5.51 during premarket trading on Monday. The stock is near its 52-week low of $4.88.
Photo via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
VIPCross-Asset Positioning Amid AI Earnings Scrutiny and the US Election
1. Markets diverged during the week. Between the October 23 and October 30 closes, BTC fell 4.78%, the Nasdaq 100 declined 1.98%, and gold and silver dropped 2.72% and 8.59%, respectively. The DAX, KOSPI, Nikkei 225 and Hang Seng advanced. We focus on differences in growth prospects, valuation sensitivity and risk exposures rather than applying a single directional view across assets. 2. Market reactions to Alphabet's and Intel's earnings brought returns on AI investment into focus. Attention is shifting from the scale of capital expenditure to revenue realization, margins and free cash flow. Lower interest rates can ease discount-rate pressure, but a sustained valuation recovery still requires support from both operating performance and financing conditions. 3. The November 3 US midterm elections and November 6 employment report are key events in the coming week. We monitor how post-election fiscal and legislative agendas may affect interest rates, the dollar and industry operating conditions. Our execution priorities are to manage leverage and concentration, retain margin and exit-liquidity buffers, and avoid treating a single political outcome as an automatic trading signal. 4. Following Binance's disclosure of a security incident, industry attention to endpoint protection, access segregation and coordinated incident response has increased. Key assets to monitor: BTC, the Nasdaq 100, crude oil and gold, alongside upcoming earnings from AAPL, AMD, PLTR, ARM, ANET and QCOM.
HYATT HOTELS CORP <H.N>: JEFFERIES RAISES TARGET PRICE TO $188 FROM $167
Italgas Raised to Buy From Hold by Berenberg
BANCORP INC <TBBK.O>: KBW CUTS TARGET PRICE TO $56 FROM $65
Crypto prices
More
